Marketing

Value is in the Eye of the Beholder

  • by

Therapeutics must demonstrate efficacy and safety to relevant regulatory authorities before they are approved for use in clinical practice. This is a relatively straightforward process, assuming the treatment positively impacts the relevant therapeutic area (e.g., ability to prevent major adverse coronary events [MACE] in coronary… Read More »Value is in the Eye of the Beholder

Langland appoints Angela Rochelle to clinical trial diversity role

  • by

Langland has announced the appointment of Angela Rochelle as account director, head of diversity initiatives in clinical trials. Rochelle will be the agency’s leading advocate for diversifying patient representation in Clinical Trial Experience (CTE). She will collaborate with Langland’s established clinical trial inclusivity taskforce—a team… Read More »Langland appoints Angela Rochelle to clinical trial diversity role

NightWare Receives the US FDA’s Approval for the First Medical Device to Stop NightMAres Related to PTSD

  • by

Shots: The US FDA has permitted marketing of a device intended for the temporary reduction of sleep disturbance related to nightmares in patients aged ≥22 yrs. suffering from nightmare disorder or PTSD Nightware utilizes Apple Watch and an iPhone that is configured and logged into… Read More »NightWare Receives the US FDA’s Approval for the First Medical Device to Stop NightMAres Related to PTSD